Compare Cognizant Technology Solutions Corp (CTSH) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Gilead Sciences, Inc. — how do they compare? Cognizant Technology Solutions Corp trades at $57.8 (market cap $26.40B), while Gilead Sciences, Inc. trades at $135.49 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 6.4× Cognizant Technology Solutions Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| CTSH | GILD | |
|---|---|---|
Market Cap | $26.40B | $168.35B |
Sector | Technology | Health |
52-Week High | $86.70 | $155.80 |
52-Week Low | $38.73 | $110.56 |
Enterprise Value | $27.44B | $191.42B |
Dividend Yield | 2.25% | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
